Authors
Giuseppe Milone, Emanuele Martorana, Maria Grazia Camuglia, Salvatore Leotta, Andrea Spadaro, Giulia Giuffrida, Gaetano Moschetti, Federica Galbo, Paola Scirè, Giulio Antonio Milone, Giordana Brunetti, Paolo Castorina
Published in
Frontiers in immunology. Volume 17. Pages 1935217. Epub Oct 16, 2026.
Abstract
After autologous haematopoietic stem cell transplantation (HSCT), the infused CD34+ cell dose is usually considered essential for assessing the adequacy of the peripheral blood progenitor cells (PBSC) inoculum.
In a cohort of 302 patients who underwent autologous haematopoietic transplantation, we investigated whether the peak peripheral blood CD34+ cell count during mobilisation could predict neutrophil engraftment.
In the overall cohort, the mean time to neutrophil engraftment was 12.2 days, and the mean infused CD34+ cell dose was 5.1 × 10^6 CD34+ cells/kg. In univariate analysis, the CD34+ cell dose (p=0.005), the PB CD34+ peak during mobilisation (p=0.0002), the number of performed apheresis (p=0.03), and the use of G-CSF (p=0.001) were significantly associated with time to neutrophil engraftment. When factors were evaluated in multivariate analysis, the PB CD34+ peak and use of G-CSF remained significant. In a ROC analysis, the PB CD34+ peak predicted delayed engraftment with an AUC of 0.695 (95% CI, 0.599-0.791). Joint stratification by PB CD34+ peak and infused CD34+ dose identified subgroups at high risk of delayed engraftment.
In patients treated by autologous HSCT and receiving an adequate dose of infused CD34+ cells, the PB CD34+ peak during mobilisation is independently associated with post-transplant neutrophil engraftment.
PMID:
42964127
Bibliographic data and abstract were imported from PubMed on 31 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 5
- Comments 0